April 1, 2019
Teva’s AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults
In clinical trials, many patients on AJOVY experienced significant reductions of at least 50% in the number of monthly migraine…
